biodelivery sciences

Raleigh pharma BDSI is hiring new CFO

Posted by Jason Parker | Oct 21, 2021

BioDelivery Sciences International will have a new CFO starting November 4, the company announced this week.

Earnings reports: Qorvo, Aerie, BDSI, VTv, First Citizens

Posted by WRAL TechWire | Aug 5, 2021

It’s earnings season, and companies across North Carolina are reporting financial results for the most recent quarter. Here’s a wrapup:

Raleigh pharma firm BDSI paying millions to acquire migraine treatment

Posted by WRAL TechWire | Aug 4, 2021

BioDelivery Sciences International is paying millions to acquire rights in the U.S. and Canada for an FDA-approved migraine treatment from Dr. Reddy’s Laboratories.

In the black: Raleigh pharma firm BDSI tops Street, sets record for full-year revenue

Posted by WRAL TechWire | Mar 10, 2021

RALEIGH – BioDelivery Sciences International (BDSI) on Wednesday reported fourth-quarter net income of $10.2 million, after reporting a loss in the same period a year earlier. And its revenues for the year jumped 40% to a record high. “The impressive momentum and growth of our innovative products has persisted...

NC life science bloodbath: BioDelivery in the black but BioCryst, Aerie, TransEnterix, Chimerix, vTv report big losses

Posted by WRAL TechWire | Nov 6, 2020

Thursday was not a good day for North Carolina life science companies. While BioDelivery Sciences reported a big profit, BioCryst, Aerie, TransEnterix, Chimerix and vTv Therapeutics all reported signifcant losses.

Raleigh’s BioDelivery Sciences announces expanded coverage for its two drugs

Posted by WRAL News | Oct 7, 2019

RALEIGH, N.C. — BioDelivery Sciences International, Inc., a Raleigh-based pharmaceutical company focused on pain management and addiction medicine, announced on Tuesday that a pharmacy benefit manager will begin providing expanded coverage for two drugs. The expanded coverage for BELBUCA and Symproic started Oct. 1 and is expected to have full...

Raleigh’s BioDelivery Sciences secures rights for opioid-induced constipation drug

Posted by WRAL News | Apr 12, 2019

The med, Symproic, is used to treat OIC in adults with chronic non-cancer pain, and has the potential to become a leading therapy option for OIC given its proven clinical profile and differentiation.

BioDelivery Sciences sues 4 rivals, alleging patent violations

Posted by WRAL TechWire | Mar 4, 2019

BioDelivery Sciences, a Raleigh-based pharmaceutical company, has filed a patent trademark lawsuit against four other companies, alleging the defendants have infringed upon a patent for its pain management drug Belbuca.